Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and imatinib

cyc 202 has been researched along with imatinib in 14 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(imatinib)		Trials
(imatinib)		Recent Studies (post-2010) (imatinib)
97973932360157

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)imatinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABLMus musculus (house mouse)0.1
Aurora kinase AHomo sapiens (human)4.3
Solute carrier family 22 member 2Homo sapiens (human)4.2
Bile salt export pumpHomo sapiens (human)10
Tyrosine-protein kinase ABL1Homo sapiens (human)0.6804
Tyrosine-protein kinase ABL1Mus musculus (house mouse)0.3704
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)2.784
Epidermal growth factor receptorHomo sapiens (human)0.0001
Carbonic anhydrase 2Homo sapiens (human)0.372
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0001
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.3
Tyrosine-protein kinase LckHomo sapiens (human)0.2667
Cyclin-dependent kinase 1Homo sapiens (human)4.3
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.8417
Tyrosine-protein kinase LynHomo sapiens (human)0.22
ATP-dependent translocase ABCB1Homo sapiens (human)5.0229
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.4
Hepatocyte growth factor receptorHomo sapiens (human)0.0216
Platelet-derived growth factor receptor betaHomo sapiens (human)0.285
Dihydrofolate reductaseEscherichia coli K-120.372
Mast/stem cell growth factor receptor KitHomo sapiens (human)1.2682
Breakpoint cluster region proteinHomo sapiens (human)0.5032
Solute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)0.473
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)5
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)0.175
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.1516
Thromboxane-A synthase Homo sapiens (human)0.198
Cyclin-dependent kinase 2Homo sapiens (human)3.318
Histamine H2 receptorHomo sapiens (human)1.963
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)0.3
5-hydroxytryptamine receptor 2AHomo sapiens (human)1.891
Sodium-dependent serotonin transporterHomo sapiens (human)1.402
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.131
Tyrosine-protein kinase ABL2Homo sapiens (human)0.156
Tyrosine-protein kinase SYKHomo sapiens (human)5
Serine/threonine-protein kinase PLK1Homo sapiens (human)4.3
Platelet-derived growth factor receptor betaRattus norvegicus (Norway rat)0.162
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.2964
Discoidin domain-containing receptor 2Homo sapiens (human)0.457
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)8.3
Multidrug and toxin extrusion protein 2Homo sapiens (human)1.625
Multidrug and toxin extrusion protein 1Homo sapiens (human)0.1467
Aurora kinase BHomo sapiens (human)4.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.9096
Aurora kinase CHomo sapiens (human)4.3

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (21.43)29.6817
2010's9 (64.29)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Russu, WA; Shallal, HM1
Buchlovič, M; Hofr, C; Kříž, Z; Potáček, M1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Dušek, J; Hanusek, J; Imramovský, A; Jorda, R; Kryštof, V; Pauk, K; Rezníčková, E1
Bazgier, V; Berka, K; Bielawska, A; Bielawski, K; Fornal, E; Gucký, T; Kryštof, V; Mojzych, M; Šubertová, V1
Ceruso, M; Kalicki, P; Karczmarzyk, Z; Kryštof, V; Mojzych, M; Supuran, CT; Urbańczyk-Lipkowska, Z; Wysocki, W1
Baltus, CB; Bazgier, V; Berka, K; Jorda, R; Kryštof, V; Marot, C; Prié, G; Viaud-Massuard, MC1
Lamie, PF1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1

Reviews

1 review(s) available for cyc 202 and imatinib

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

13 other study(ies) available for cyc 202 and imatinib

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
New PAH derivatives functionalized by cyclic nitrone framework: synthetic design, anti-proliferative activity and interaction with DNA.
    Bioorganic & medicinal chemistry, 2013, Mar-01, Volume: 21, Issue:5

    Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; DNA; Drug Design; HCT116 Cells; Humans; Intercalating Agents; K562 Cells; MCF-7 Cells; Molecular Docking Simulation; Nitrogen Oxides; Nucleic Acid Conformation; Polycyclic Aromatic Hydrocarbons; Structure-Activity Relationship

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines.
    European journal of medicinal chemistry, 2013, Volume: 68

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Humans; Inhibitory Concentration 50; Molecular Structure

2013
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
    European journal of medicinal chemistry, 2014, May-06, Volume: 78

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; K562 Cells; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Triazines; Tumor Cells, Cultured

2014
New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity.
    Bioorganic & medicinal chemistry, 2015, Apr-01, Volume: 23, Issue:7

    Topics: Crystallography, X-Ray; Enzyme Inhibitors; Humans; K562 Cells; MCF-7 Cells; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate

2015
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
    European journal of medicinal chemistry, 2016, Jan-27, Volume: 108

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Indoles; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship

2016
RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
    Bioorganic & medicinal chemistry letters, 2016, 07-01, Volume: 26, Issue:13

    Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; K562 Cells; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Structure-Activity Relationship

2016
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Development of an
    Journal of medicinal chemistry, 2021, 03-11, Volume: 64, Issue:5

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic

2021
chemdatabank.com